Alpha Therapeutic Corporation Names David Hirsch as Senior Vice President, Worldwide Sales and Marketing.Business Editors & Health/Medical Writers BIOWIRE2K LOS ANGELES--(BW HealthWire)--June 13, 2002 Alpha Therapeutic Corporation today announced the appointment of David Hirsch as Senior Vice President, Worldwide Sales and Marketing. He will lead efforts to further expand Alpha's position in the global market for plasma derived products. Previously, Hirsch was Vice President, Sales and Marketing at Nexell Therapeutics, which developed stem cell therapies for cancer treatment. He has extensive experience in pharmaceutical sales and marketing with Boehringer Mannheim Pharmaceuticals and Schering-Plough. His health care experience also includes senior management positions at GFI Pharmaceutical Services, a clinical research organization, and CTRC CTRC Cancer Therapy Research Center CTRC Cisco Transaction Connection CTRC Cooling Technologies Research Center (Purdue University) CTRC California Trolley and Railroad Corporation (San Jose, CA) Research Foundation, a non-profit cancer research and treatment organization. He has a bachelor's degree in microbiology from Indiana University. "David Hirsch is a strong addition to our senior management team. His leadership skills and pharmaceutical industry experience will help Alpha as we expand into new markets and launch new therapies for improved patient care," said Edward A. Colton, President & CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . New therapies on the horizon include an alpha-1 proteinase proteinase /pro·tein·ase/ (pro´ten-as?) endopeptidase. pro·tein·ase n. A protease that begins the hydrolytic breakdown of proteins usually by splitting them into polypeptide chains. inhibitor product for treatment of emphysema caused by a genetic deficiency of the alpha-1 protein. The company has filed an application with the U.S. Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) and is actively pursuing licensure of this important product. Additionally, Alpha has a pending application with the FDA for a new indication for its existing Factor VIII product, Alphanate(R), Antihemophilic Factor (Human). Currently licensed for treatment of hemophilia A, Alphanate gained approval for treatment of von Willebrand disease Von Willebrand Disease Definition Von Willebrand disease is caused by a deficiency or an abnormality in a protein called von Willebrand factor and is characterized by prolonged bleeding. in the United Kingdom in 2001 and in Italy in 2002. "Alpha has a solid product portfolio and a long history in the plasma industry. I welcome the opportunity to launch these new therapies and to work with our customers to provide a consistent, reliable supply of plasma products," said Hirsch. Alpha is a leading developer of plasma derived biopharmaceutical products which are sourced, tested and manufactured in the United States. Alpha's product portfolio includes coagulation factors, immune globulin and albumin, which are distributed domestically to hospitals, pharmacies, home care companies and physicians. Internationally, Alpha's products are marketed through a network of subsidiaries, affiliates and local offices in Asia, Europe and Latin America. The raw material for Alpha's products, human blood plasma, is collected in the United States. The company owns 42 plasma collection centers strategically located across the U.S. and has a central testing laboratory in Memphis, TN, which conducts serological serological pertaining to or emanating from serology. serological test one involving examination of blood serum usually for antibody. screening tests on all plasma donations. Plasma donations are also screened for HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. and hepatitis C utilizing Polymerase Chain Reaction polymerase chain reaction (pŏl`ĭmərās') (PCR), laboratory process in which a particular DNA segment from a mixture of DNA chains is rapidly replicated, producing a large, readily analyzed sample of a piece of DNA; the process is (PCR PCR polymerase chain reaction. PCR abbr. polymerase chain reaction Polymerase chain reaction (PCR) ) testing. This testing is conducted by National Genetics Institute (NGI). All of Alpha's plasma derived products are manufactured at its FDA licensed fractionation fractionation /frac·tion·a·tion/ (frak?shun-a´shun) 1. in radiology, division of the total dose of radiation into small doses administered at intervals. 2. facility in Los Angeles. Over the last several years, Alpha has made a significant investment in facility upgrades, including capital improvements and enhanced compliance with current Good Manufacturing Practices (cGMPs). Alpha is committed to providing high quality, safe and cost effective therapeutics for improved patient care worldwide. Additional company information is available at www.alphather.com. |
|
||||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion